Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.
CDX2
Colorectal cancer
Guanylate cyclase C
Guanylin
Serrated adenoma
Tubular adenoma
Journal
Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
12
09
2018
revised:
16
11
2018
accepted:
23
11
2018
pubmed:
5
2
2019
medline:
19
11
2019
entrez:
5
2
2019
Statut:
ppublish
Résumé
Colorectal cancers (CRCs) initiate through distinct mutations, including in APC pathway components leading to tubular adenomas (TAs); in BRAF, with epigenetic silencing of CDX2, leading to serrated adenomas (SAs); and in the DNA mismatch repair machinery driving microsatellite instability (MSI). Transformation through the APC pathway involves loss of the hormone GUCA2A that silences the tumor-suppressing receptor GUCY2C. Indeed, oral hormone replacement is an emerging strategy to reactivate GUCY2C and prevent CRC initiation and progression. Moreover, retained expression by tumors arising from TAs has established GUCY2C as a diagnostic and therapeutic target to prevent and treat metastatic CRC. Here, we defined the potential role of the GUCA2A-GUCY2C axis and its suitability as a target in tumors arising through the SA and MSI pathways. GUCA2A hormone expression was eliminated in TAs, SAs, and MSI tumors compared to their corresponding normal adjacent tissues. In contrast to the hormone, the tumor-suppressing receptor GUCY2C was retained in TA and MSI tumors. Surprisingly, GUCY2C expression was nearly eliminated in SAs, reflecting loss of the transcription factor CDX2. Changes in the GUCA2A-GUCY2C axis in human SAs and MSI tumors were precisely recapitulated in genetic mouse models. These data reveal the possibility of GUCA2A loss silencing GUCY2C in the pathophysiology of, and oral hormone replacement to restore GUCY2C signaling to prevent, MSI tumors. Also, they highlight the potential for targeting GUCY2C to prevent and treat metastases arising from TA and MSI tumors. In contrast, loss of GUCY2C excludes patients with SAs as candidates for GUCY2C-based prevention and therapy.
Identifiants
pubmed: 30716341
pii: S0046-8177(19)30007-3
doi: 10.1016/j.humpath.2018.11.032
pmc: PMC6988773
mid: NIHMS1548045
pii:
doi:
Substances chimiques
GUCY2C protein, human
EC 4.6.1.2
Receptors, Enterotoxin
EC 4.6.1.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-114Subventions
Organisme : NCI NIH HHS
ID : F30 CA232469
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206026
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008562
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204481
Pays : United States
Organisme : NIDDK NIH HHS
ID : F30 DK103492
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA056036
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
JAMA. 2009 Feb 18;301(7):745-52
pubmed: 19224751
Am J Surg Pathol. 2004 Nov;28(11):1452-9
pubmed: 15489648
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Gastroenterology. 2010 Mar;138(3):993-1002.e1
pubmed: 19931261
Cancer Res. 2000 Sep 15;60(18):5151-7
pubmed: 11016642
Endocrinology. 2008 Sep;149(9):4486-98
pubmed: 18499760
N Engl J Med. 2018 Aug 23;379(8):764-773
pubmed: 30134129
Genes Dev. 2007 Feb 15;21(4):379-84
pubmed: 17299132
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
J Natl Cancer Inst. 2008 Jul 2;100(13):950-61
pubmed: 18577748
Cancer Immunol Res. 2018 May;6(5):509-516
pubmed: 29615399
Cancer Prev Res (Phila). 2017 Jun;10(6):345-354
pubmed: 28396341
Cancer Res. 2016 Jan 15;76(2):339-46
pubmed: 26773096
J Exp Med. 2018 Mar 5;215(3):911-926
pubmed: 29439001
Mod Pathol. 2018 Mar;31(3):495-504
pubmed: 29148535
Gastroenterology. 2000 Jul;119(1):89-96
pubmed: 10889158
Hum Pathol. 2014 Aug;45(8):1704-12
pubmed: 24908142
Gut. 2004 Apr;53(4):573-80
pubmed: 15016754
Cell Rep. 2017 Dec 26;21(13):3833-3845
pubmed: 29281831
Physiol Rev. 2016 Apr;96(2):751-804
pubmed: 27030537
Gut. 2009 Jan;58(1):90-6
pubmed: 18832519
Cancer Res. 2009 Apr 15;69(8):3537-44
pubmed: 19351847
J Gastrointest Oncol. 2015 Dec;6(6):660-7
pubmed: 26697199
Oncotarget. 2014 Oct 15;5(19):9460-71
pubmed: 25294806
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Science. 1997 Mar 21;275(5307):1787-90
pubmed: 9065402
Gastroenterology. 2007 Aug;133(2):599-607
pubmed: 17681179
Gastroenterology. 2010 Jan;138(1):241-54
pubmed: 19737566
Dig Dis. 2015;33(1):28-37
pubmed: 25531494
N Engl J Med. 2016 Mar 17;374(11):1065-75
pubmed: 26981936
Hum Pathol. 2010 Jan;41(1):123-8
pubmed: 19800103
Ann Intern Med. 2016 Jun 21;164(12):836-45
pubmed: 27064677
World J Gastroenterol. 2016 Sep 28;22(36):8070-7
pubmed: 27688649
J Clin Invest. 2011 Sep;121(9):3578-88
pubmed: 21865642
Cancer Res. 2017 Sep 15;77(18):5095-5106
pubmed: 28916678
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Elife. 2017 Jan 10;6:
pubmed: 28072391
N Engl J Med. 2016 Jan 21;374(3):211-22
pubmed: 26789870
Lab Invest. 1998 Jan;78(1):101-8
pubmed: 9461126